Psychopharmacol
Bull 1996;32(2):275-81
Clinical issues in the pharmacotherapy of African-Americans.
Lawson WB.
Psychiatry Service, North Little Rock VA Medical Center, AR 72114, USA.
African-Americans have poorer outcomes than Caucasians in general health
and mental health systems possibly due to lesser access to services, particularly
pharmacotherapy in mental health systems. A review of the literature revealed
that African-Americans are more likely to be overdiagnosed as having a
psychotic illness. Consequently, antipsychotic medication may be overprescribed.
Poorer patient compliance, delays in seeking treatment, higher prescribed
dosages, and more PRN use of medication by providers add to racial differences
in treatment outcome. African-Americans also are reported to be at a greater
risk than Caucasians for medication side effects and adverse consequences.
These problems may be exacerbated by ethnic differences in pharmacokinetics.
Newer pharmacological agents may be more helpful for minorities because
they are better tolerated, produce fewer side effects, and have better
efficacy. However, African-Americans still are underrepresented in clinical
trials and have limited access to these agents. Race and ethnicity need
to be considered in maximizing pharmacotherapy and to better understand
treatment outcome.
PMID: 8783898 [PubMed - indexed for MEDLINE]